Kevin K. Brown

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

Kevin R. Flaherty, Athol U. Wells, Vincent Cottin et al. · New England Journal of Medicine · 2019 · 2.3K citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacotherapy +11

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

Francis X. McCormack, Yoshikazu Inoue, Joel Moss et al. · New England Journal of Medicine · 2011 · 1.1K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis

Harold R. Collard, Talmadge E. King, Becki Bucher Bartelson et al. · American Journal of Respiratory and Critical Care Medicine · 2003 · 762 citations

Medicine, Clinical Sciences, Internal Medicine +17

A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis

Ganesh Raghu, Kevin K. Brown, Williamson Z. Bradford et al. · New England Journal of Medicine · 2004 · 652 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12